Glaukos Receivables 2014-2024 | GKOS

Glaukos receivables for the quarter ending December 31, 2024 were $0.061B, a 52.43% increase year-over-year.

  • Glaukos receivables for 2024 were $0.061B, a 52.43% increase from 2023.
  • Glaukos receivables for 2023 were $0.04B, a 10.47% increase from 2022.
  • Glaukos receivables for 2022 were $0.036B, a 7.88% increase from 2021.

Glaukos Receivables 2014-2024 | GKOS

  • Glaukos receivables for 2024 were $0.061B, a 52.43% increase from 2023.
  • Glaukos receivables for 2023 were $0.04B, a 10.47% increase from 2022.
  • Glaukos receivables for 2022 were $0.036B, a 7.88% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$171.9B
Thermo Fisher Scientific (TMO)$161.4B
Alcon (ALC)$45.6B
Edwards Lifesciences (EW)$42B
IDEXX Laboratories (IDXX)$33.3B
DexCom (DXCM)$26.9B
IQVIA Holdings (IQV)$25.4B
STERIS (STE)$21.8B
Mettler-Toledo (MTD)$20.9B
Waters (WAT)$19.1B
SONOVA HOLDING (SONVY)$17.3B
Fresenius Medical Care AG KGaA (FMS)$13.9B
Hologic (HOLX)$12.9B
Sysmex ADR (SSMXY)$11.8B
Penumbra (PEN)$10.7B
Globus Medical (GMED)$9.8B
Masimo (MASI)$8.2B
Teleflex (TFX)$6B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3B
PROCEPT BioRobotics (PRCT)$2.9B
Veracyte (VCYT)$2.4B
Nihon Kohden (NHNKY)$2.1B
LivaNova (LIVN)$1.9B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.5B
Integra LifeSciences Holdings (IART)$1.2B
Pulse Biosciences (PLSE)$1.2B
Tandem Diabetes Care (TNDM)$1.1B
Paragon 28 (FNA)$1.1B